Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. (ESPR) is a US-based biotechnology company focused on lowering LDL cholesterol through oral therapies, principally bempedoic acid marketed as Nexletol and the combination Nexlizet. As a small‑cap, commercial-stage player (market capitalisation about $647.7 million), Esperion generates revenue from product sales while continuing to invest in clinical development and market access. Investors should note that growth depends on physician and patient adoption, pricing and reimbursement decisions, and the outcome of ongoing clinical and regulatory activity. The company faces established competition from statins and newer injectable therapies, which can influence market share. Financial results and the share price can be volatile for biotech firms of this size, often driven by trial data, sales trends and financing events. This summary is for general, educational purposes only and is not personal investment advice; suitability depends on your objectives, timeframe and risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts advise purchasing Esperion's stock with a target price of $6.08, indicating growth potential.
Financial Health
Esperion Therapeutics is generating strong revenue and cash flow, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ESPR
Cardio-Metabolic Drugs: Beyond Weight Loss Benefits
Following new data showing Novo Nordisk's Wegovy has superior cardiovascular benefits over a key rival, the competitive landscape for weight-loss drugs has intensified. This theme focuses on the pharmaceutical giants battling for dominance and the innovative biotechs whose research in related metabolic and cardiovascular fields is now more valuable than ever.
Published: September 1, 2025
Explore BasketThe Global Weight-Loss Drug Price Shift
Eli Lilly's significant price hike for Mounjaro in the UK, driven by U.S. political pressure, highlights a new global pricing strategy for blockbuster drugs. This creates a potential opportunity for competitors in the booming weight-loss market as patients and providers may seek more affordable alternatives.
Published: August 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercial traction
Products are on the market and sales growth will reflect physician adoption and payer support; revenue can be uneven and subject to market dynamics.
Mechanism & pipeline
Bempedoic acid offers an oral mechanism for lowering LDL and there are ongoing studies; trial results and regulatory updates may materially change prospects.
Competitive landscape
Operates in a large but competitive lipid‑lowering market where statins and injectables are established; pricing and new entrants are important risks to monitor.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
